Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1993 Jun;68(6):788–792. doi: 10.1136/adc.68.6.788

Aerosol antibiotic treatment in cystic fibrosis.

J M Littlewood 1, S W Smye 1, H Cunliffe 1
PMCID: PMC1029378  PMID: 8333776

Full text

PDF
788

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvine G. F., Rodgers P., Fitzsimmons K. M., Ahrens R. C. Disposable jet nebulizers. How reliable are they? Chest. 1992 Feb;101(2):316–319. doi: 10.1378/chest.101.2.316. [DOI] [PubMed] [Google Scholar]
  2. Brett M. M., Simmonds E. J., Ghoneim A. T., Littlewood J. M. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child. 1992 Sep;67(9):1086–1088. doi: 10.1136/adc.67.9.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chua H. L., Collis G. G., Le Souëf P. N. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J. 1990 Nov;3(10):1114–1116. [PubMed] [Google Scholar]
  4. Clarke S. W., Newman S. P. Therapeutic aerosols 2--Drugs available by the inhaled route. Thorax. 1984 Jan;39(1):1–7. doi: 10.1136/thx.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clay M. M., Pavia D., Newman S. P., Clarke S. W. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax. 1983 Oct;38(10):755–759. doi: 10.1136/thx.38.10.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clay M. M., Pavia D., Newman S. P., Lennard-Jones T., Clarke S. W. Assessment of jet nebulisers for lung aerosol therapy. Lancet. 1983 Sep 10;2(8350):592–594. doi: 10.1016/s0140-6736(83)90679-7. [DOI] [PubMed] [Google Scholar]
  7. Cockcroft D. W., Hurst T. S., Gore B. P. Importance of evaporative water losses during standardized nebulized inhalation provocation tests. Chest. 1989 Sep;96(3):505–508. doi: 10.1378/chest.96.3.505. [DOI] [PubMed] [Google Scholar]
  8. Collis G. G., Cole C. H., Le Souëf P. N. Dilution of nebulised aerosols by air entrainment in children. Lancet. 1990 Aug 11;336(8711):341–343. doi: 10.1016/0140-6736(90)91880-j. [DOI] [PubMed] [Google Scholar]
  9. Conneally E., Cafferkey M. T., Daly P. A., Keane C. T., McCann S. R. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990 Jun;5(6):403–406. [PubMed] [Google Scholar]
  10. Everard M. L., Clark A. R., Milner A. D. Drug delivery from jet nebulisers. Arch Dis Child. 1992 May;67(5):586–591. doi: 10.1136/adc.67.5.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gappa M., Steinkamp G., Tümmler B., von der Hardt H. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Scand J Gastroenterol Suppl. 1988;143:74–76. [PubMed] [Google Scholar]
  12. Goldman J. M., Bayston S. M., O'Connor S., Meigh R. E. Inhaled micronised gentamicin powder: a new delivery system. Thorax. 1990 Dec;45(12):939–940. doi: 10.1136/thx.45.12.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  14. Jensen T., Pedersen S. S., Garne S., Heilmann C., Høiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987 Jun;19(6):831–838. doi: 10.1093/jac/19.6.831. [DOI] [PubMed] [Google Scholar]
  15. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985 Apr 13;1(8433):865–865. doi: 10.1016/s0140-6736(85)92222-6. [DOI] [PubMed] [Google Scholar]
  16. MacLusky I. B., Gold R., Corey M., Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42–48. doi: 10.1002/ppul.1950070110. [DOI] [PubMed] [Google Scholar]
  17. Maxwell D. The role of antibiotics given by inhalation in chronic chest disease. J Antimicrob Chemother. 1983 Mar;11(3):203–206. doi: 10.1093/jac/11.3.203. [DOI] [PubMed] [Google Scholar]
  18. Newman S. P., Agnew J. E., Pavia D., Clarke S. W. Inhaled aerosols: lung deposition and clinical applications. Clin Phys Physiol Meas. 1982 Feb;3(1):1–20. doi: 10.1088/0143-0815/3/1/001. [DOI] [PubMed] [Google Scholar]
  19. Newman S. P., Clarke S. W. Nebulisers: uses and abuses. Arch Dis Child. 1986 May;61(5):424–425. doi: 10.1136/adc.61.5.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Newman S. P., Pavia D., Garland N., Clarke S. W. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl. 1982;119:57–65. [PubMed] [Google Scholar]
  21. Newman S. P., Pellow P. G., Clarke S. W. In vitro comparison of DeVilbiss jet and ultrasonic nebulizers. Chest. 1987 Dec;92(6):991–994. doi: 10.1378/chest.92.6.991. [DOI] [PubMed] [Google Scholar]
  22. Newman S. P., Pellow P. G., Clay M. M., Clarke S. W. Evaluation of jet nebulisers for use with gentamicin solution. Thorax. 1985 Sep;40(9):671–676. doi: 10.1136/thx.40.9.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Newman S. P., Woodman G., Clarke S. W. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988 Apr;43(4):318–322. doi: 10.1136/thx.43.4.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Newman S. P., Woodman G., Clarke S. W. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988 Apr;43(4):318–322. doi: 10.1136/thx.43.4.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nolan G., Moivor P., Levison H., Fleming P. C., Corey M., Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr. 1982 Oct;101(4):626–630. doi: 10.1016/s0022-3476(82)80726-9. [DOI] [PubMed] [Google Scholar]
  26. Nolan G., Moivor P., Levison H., Fleming P. C., Corey M., Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr. 1982 Oct;101(4):626–630. doi: 10.1016/s0022-3476(82)80726-9. [DOI] [PubMed] [Google Scholar]
  27. O'Callaghan C., Clark A. R., Milner A. D. Why nebulise for more than five minutes? Arch Dis Child. 1989 Sep;64(9):1270–1273. doi: 10.1136/adc.64.9.1270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Oehling A., Giron M., Subira M. L. Aerosol chemotherapy in bronchopulmonary candidiasis. Respiration. 1975;32(2):179–184. doi: 10.1159/000193647. [DOI] [PubMed] [Google Scholar]
  29. Schaad U. B., Wedgwood-Krucko J., Suter S., Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr. 1987 Oct;111(4):599–605. doi: 10.1016/s0022-3476(87)80130-0. [DOI] [PubMed] [Google Scholar]
  30. Semsarian C. Efficacy of inhaled tobramycin in cystic fibrosis. J Paediatr Child Health. 1990 Apr;26(2):110–111. doi: 10.1111/j.1440-1754.1990.tb02402.x. [DOI] [PubMed] [Google Scholar]
  31. Simmonds E. J., Conway S. P., Ghoneim A. T., Ross H., Littlewood J. M. Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child. 1990 Aug;65(8):874–877. doi: 10.1136/adc.65.8.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Skobel P. Zum Problem pilzbedingter Superinfektionen der Atemorgane sowie deren Behandlung mit Inhalationen und Instillationen von Amphotericin B und Moronal-Reinsubstanz. Med Welt. 1966 Dec 10;50:2755–2759. [PubMed] [Google Scholar]
  33. Smith A. L., Ramsey B. W., Hedges D. L., Hack B., Williams-Warren J., Weber A., Gore E. J., Redding G. J. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7(4):265–271. doi: 10.1002/ppul.1950070413. [DOI] [PubMed] [Google Scholar]
  34. Smye S. W., Jollie M. I., Cunliffe H., Littlewood J. M. Measurement and prediction of drug solvent losses by evaporation from a jet nebuliser. Clin Phys Physiol Meas. 1992 May;13(2):129–134. doi: 10.1088/0143-0815/13/2/004. [DOI] [PubMed] [Google Scholar]
  35. Smye S. W., Jollie M. I., Littlewood J. M. A mathematical model of some aspects of jet nebuliser performance. Clin Phys Physiol Meas. 1991 Aug;12(3):289–300. doi: 10.1088/0143-0815/12/3/010. [DOI] [PubMed] [Google Scholar]
  36. Smye S. W., Shaw A., Norwood H. M., Littlewood J. M. Some factors influencing the efficiency of a jet nebuliser system. Clin Phys Physiol Meas. 1990 May;11(2):167–175. doi: 10.1088/0143-0815/11/2/007. [DOI] [PubMed] [Google Scholar]
  37. Stead R. J., Hodson M. E., Batten J. C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987 Jul;81(3):272–279. doi: 10.1016/0007-0971(87)90161-6. [DOI] [PubMed] [Google Scholar]
  38. Steinkamp G., Tümmler B., Gappa M., Albus A., Potel J., Döring G., von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989;6(2):91–98. doi: 10.1002/ppul.1950060207. [DOI] [PubMed] [Google Scholar]
  39. Stephens D., Garey N., Isles A., Levison H., Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis. 1983 May-Jun;2(3):209–211. doi: 10.1097/00006454-198305000-00007. [DOI] [PubMed] [Google Scholar]
  40. Stout S. A., Derendorf H. Local treatment of respiratory infections with antibiotics. Drug Intell Clin Pharm. 1987 Apr;21(4):322–329. doi: 10.1177/106002808702100402. [DOI] [PubMed] [Google Scholar]
  41. Tablan O. C., Martone W. J., Doershuk C. F., Stern R. C., Thomassen M. J., Klinger J. D., White J. W., Carson L. A., Jarvis W. R. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest. 1987 Apr;91(4):527–532. doi: 10.1378/chest.91.4.527. [DOI] [PubMed] [Google Scholar]
  42. Thomas S. H., Langford J. A., George R. D., Geddes D. M. Improving the efficiency of drug administration with jet nebulisers. Lancet. 1988 Jan 16;1(8577):126–126. doi: 10.1016/s0140-6736(88)90331-5. [DOI] [PubMed] [Google Scholar]
  43. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]
  44. Wall M. A., Terry A. B., Eisenberg J., McNamara M., Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet. 1983 Jun 11;1(8337):1325–1325. doi: 10.1016/s0140-6736(83)92428-5. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES